The probe follows a series of disappointing financial disclosures that decimated the company's market valuation. On April 8, 2025, shares plummeted 46% after CVRx reported weak preliminary results, blaming the underperformance on an inexperienced sales team. A second major decline occurred on May 9, 2025, when the stock dropped nearly 39% following an admission that internal salesforce restructuring was more disruptive than previously disclosed.
In section Releases
Pomerantz LLP Launches Investigation Into CVRx Securities Practices
A 60% single-day stock collapse following repeated downward guidance revisions has triggered a formal investigation into CVRx, Inc. New York-based Pomerantz LLP is currently scrutinizing whether the medical device company and its leadership engaged in securities fraud or unlawful business practices during a period of intense salesforce turnover.
Financial instability persisted into 2026, culminating in an August 7 crash where CVRx shares fell by 59.76% to close at $2.39. This latest slide was prompted by a reduced revenue outlook of $58 million to $60 million and management’s admission that rapid hiring had overwhelmed training processes. Beyond operational struggles, the company disclosed that it received a Department of Justice civil investigative demand in May 2026 regarding its sales and marketing strategies. Investors affected by these losses are being urged to contact Pomerantz LLP to discuss potential litigation regarding breaches of fiduciary duty and corporate misconduct.
Comments (0)
No comments yet. Be the first!